Jorge Santos da Silva - 08 Dec 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role: Chief Executive Officer, Director
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva
Issuer symbol: MLTX
Transactions as of: 08 Dec 2025
Net transactions value: -$2,974,700
Form type: 4
Filing time: 10 Dec 2025, 16:29:45 UTC
Previous filing: 03 Mar 2025
Next filing: 22 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Santos da Silva Jorge	Chief Executive Officer, Director	C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND	/s/ Matthias Bodenstedt, Attorney-in-fact for Jorge Santos da Silva	10 Dec 2025	0001920509

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLTX	Class A ordinary shares, par value $0.0001 per share	Sale	$1,960,400	-130,000	-4.2%	$15.08	2,948,577	08 Dec 2025	Direct	F1, F2
transaction	MLTX	Class A ordinary shares, par value $0.0001 per share	Sale	$1,014,300	-70,000	-2.4%	$14.49	2,878,577	09 Dec 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.
F2	The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Content

Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.